LYCOS RETRIEVER 
Chiron: Chiron Corporation
built 211 days ago
Chiron entered 1991 with a strong balance sheet. In July of that year, the company purchased a rival biotechnology firm, Cetus Corporation, for $650 million in stock. Cetus's major product was a highly touted cancer treatment called Proleukin or interleukin-2, which its EuroCetus division had been selling in Europe for several years. The FDA had refused to approve use of the drug in the United States... and Cetus's chairperson resigned his post, leaving the company without direction and with a product whose image had been greatly tarnished. Chiron stepped in, continued testing Proleukin as the FDA had requested, and merged Cetus's projects with its own. With the purchase, Chiron also acquired a state-of-the art research facility, not far from its own headquarters in Emeryville, California.
Source:
EMERYVILLE, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR - News) today announced a new collaboration agreement with CSL Limited, an Australian-based pharmaceutical company, to develop a therapeutic hepatitis C vaccine. Under the terms of the joint development agreement, Chiron will provide its novel hepatitis C virus (HCV) antigens, and CSL will contribute its proprietary ISCOMATRIX® adjuvant technology.
Source:
EMERYVILLE, Calif., Jul 6, 2004 /PRNewswire-FirstCall via COMTEX/ -- Chiron Corporation (Nasdaq: CHIR) and Sagres Discovery announced today Chiron has acquired Sagres. Sagres, a privately held company headquartered in Davis, Calif., focuses on the discovery and validation of targets with potential application to the development of cancer therapeutics. Financial terms of the acquisition were not disclosed.
Source:
EMERYVILLE, Calif., March 13 /PRNewswire-FirstCall/ -- Chiron Corporation today announced that it has been granted United States Patent No. 6,531,276. This patent is directed to nucleic acid testing (NAT) methods for HIV-1. In addition to its application in screening blood donations, this technology plays an important role in the treatment of HIV-positive patients.
Source:
EMERYVILLE, Calif., Oct. 23, 2002 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) announced today decisions on three clinical development programs. Chiron is stopping SILCAAT, a Phase III study for recombinant human interleukin-2 (IL-2, aldesleukin) in patients with HIV.
Source:
EMERYVILLE, Calif., Aug. 14 /PRNewswire/ -- Chiron Corporation (Nasdaq: CHIR) and PathoGenesis Corporation announced today that they have entered into a definitive agreement for Chiron to purchase PathoGenesis for $38.50 per share in cash, or about $700 million. The transaction will be accounted for under the purchase method and is projected to close in the third or fourth quarter of this year.
Source:
MORE ABOUT
Chiron Corporation